We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Endo’s Second Complete Response Delays Aveed NDA
Endo’s Second Complete Response Delays Aveed NDA
December 4, 2009
Endo Pharmaceuticals has received its second complete response letter from the FDA for its injectable Aveed drug to treat low testosterone levels.